Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 2/20 | 0.34 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.31 |
| ▸ | BRD4 | O60885 | 1/20 | 0.30 |
| ▸ | F9 | P00740 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL964440 | 0.94 | P2RX7 (0.33) | PDE2AF9 | |
| SCHEMBL961922 | 0.91 | PSEN1 (0.35) | PDE2ATRPA1 | |
| SCHEMBL965441 | 0.89 | PSEN1 (0.35) | PDE2ATRPA1 | |
| SCHEMBL962047 | 0.84 | P2RX7 (0.34) | — | |
| SCHEMBL966985 | 0.83 | PSEN1 (0.35) | F9 | |
| SCHEMBL2536691 | 0.83 | PDE2A (0.34) | PDE2ATRPA1 | |
| SCHEMBL965660 | 0.82 | PSEN1 (0.34) | PDE2A | |
| SCHEMBL962717 | 0.80 | PSEN1 (0.42) | F9 | |
| SCHEMBL961791 | 0.79 | PSEN1 (0.42) | — | |
| SCHEMBL961782 | 0.79 | TRPA1 (0.33) | TRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2379553-B1 | BICYCLIC COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL MYERS SQUIBB CO (US) | 2013-06-26 | — | — | EP | disclosed |
| US-8349880-B2 | Bicyclic compounds for the reduction of beta-amyloid production | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-01-08 | — | — | US | disclosed |
| US-20110015175-A1 | Bicyclic Compounds for the Reduction of Beta-Amyloid Production | BRISTOL-MYERS SQUIBB COMPANY | 2011-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110015175-A1 | Bicyclic Compounds for the Reduction of Beta-Amyloid Production | APP, BACE1, APBA1 | PDE2A 1826/4885TRPA1 4065/4885BRD4 1340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.